UCB SA

BRSE:UNC Stock Report

Market Cap: CHF 45.7b

UCB Valuation

Is UNC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of UNC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: UNC (CHF241.52) is trading below our estimate of future cash flow value (CHF583.38)

Significantly Below Future Cash Flow Value: UNC is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for UNC?

Key metric: As UNC is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for UNC. This is calculated by dividing UNC's market cap by their current earnings.
What is UNC's PE Ratio?
PE Ratio31.9x
Earnings€1.56b
Market Cap€49.68b

Price to Earnings Ratio vs Peers

How does UNC's PE Ratio compare to its peers?

The above table shows the PE ratio for UNC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average44.5x
SDZ Sandoz Group
39.7x16.94%CHF 29.3b
GALD Galderma Group
81.8x23.93%CHF 40.5b
DESN Dottikon ES Holding
35.8x13.30%CHF 3.7b
NOVN Novartis
20.8x9.34%CHF 227.5b
UNC UCB
31.9x17.14%CHF 49.7b

Price-To-Earnings vs Peers: UNC is good value based on its Price-To-Earnings Ratio (31.9x) compared to the peer average (44.4x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does UNC's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
UNC 31.9xIndustry Avg. 21.0xNo. of Companies8PE01632486480+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: UNC is expensive based on its Price-To-Earnings Ratio (31.9x) compared to the European Pharmaceuticals industry average (20.9x).

Price to Earnings Ratio vs Fair Ratio

What is UNC's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

UNC PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio31.9x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate UNC's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst UNC forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
CHF 264.16
0%
11.65%CHF 310.95CHF 178.34n/a19
May ’27n/a
CHF 260.76
0%
12.87%CHF 311.47CHF 178.64n/a20
Apr ’27n/a
CHF 262.01
0%
12.87%CHF 312.96CHF 179.49n/a20
Mar ’27n/a
CHF 257.56
0%
13.66%CHF 309.00CHF 163.59n/a20
Feb ’27n/a
CHF 242.75
0%
16.43%CHF 284.82CHF 135.06n/a19
Jan ’27n/a
CHF 247.70
0%
11.84%CHF 280.77CHF 168.46n/a18
Dec ’26n/a
CHF 238.61
0%
13.42%CHF 280.10CHF 149.39n/a18
Nov ’26n/a
CHF 236.01
0%
13.95%CHF 278.27CHF 148.41n/a18
Oct ’26n/a
CHF 220.17
0%
10.60%CHF 252.31CHF 149.52n/a18
Sep ’26n/a
CHF 210.16
0%
11.49%CHF 239.07CHF 150.01n/a18
Aug ’26n/a
CHF 203.39
0%
11.75%CHF 237.72CHF 149.16n/a18
Jul ’26n/a
CHF 197.50
0%
12.57%CHF 233.54CHF 126.11CHF 237.0217
Jun ’26n/a
CHF 194.70
0%
12.89%CHF 233.52CHF 126.10n/a18
May ’26n/a
CHF 195.49
0%
12.89%CHF 234.46CHF 126.61n/a18
Apr ’26n/a
CHF 201.26
0%
11.85%CHF 237.78CHF 128.40n/a18
Mar ’26n/a
CHF 195.90
0%
13.60%CHF 234.09CHF 126.41n/a18
Feb ’26n/a
CHF 182.67
0%
22.92%CHF 236.48CHF 93.65n/a18
Jan ’26n/a
CHF 177.34
0%
22.54%CHF 231.79CHF 91.79n/a18
Dec ’25n/a
CHF 167.27
0%
22.84%CHF 232.53CHF 92.08n/a18
Nov ’25n/a
CHF 161.59
0%
20.74%CHF 235.86CHF 93.40n/a18
Oct ’25n/a
CHF 154.80
0%
16.51%CHF 187.34CHF 92.73n/a19
Sep ’25n/a
CHF 156.00
0%
16.47%CHF 190.24CHF 94.17n/a19
Aug ’25n/a
CHF 147.21
0%
16.40%CHF 188.54CHF 93.33n/a19
Jul ’25n/a
CHF 133.93
0%
14.62%CHF 162.97CHF 94.90n/a19
CHF 267.87
Fair Value
9.8% undervalued intrinsic discount
19
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/09 12:24
End of Day Share Price 2026/06/08 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

UCB SA is covered by 37 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Charles PitmanBarclays
Brian BourdotBarclays
Kerry HolfordBerenberg